Mozobil (Plerixafor)

Plerixafor, the active ingredient in Mozobil, is a CXCR4 antagonist presented as a 0.24 mg/mL injection solution for subcutaneous use. Approved in the European Union, it mobilizes hematopoietic stem cells into peripheral blood, facilitating collection for autologous transplantation in patients with non‑Hodgkin lymphoma and multiple myeloma.

GNH USA supplies Mozobil as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide, offering regulatory‑compliant sourcing and logistics for biologic injectables and ensures cold‑chain handling where required through its global network.

Mozobil (plerixafor) is used to mobilize hematopoietic stem cells in hematologic malignancies. - Non‑Hodgkin lymphoma: enables collection of sufficient hematopoietic stem cells for autologous transplantation. - Multiple myeloma: facilitates stem cell harvest to support autologous transplantation. - Autologous stem cell transplantation procedures: improves peripheral blood stem cell yield for patients requiring transplant.

Plerixafor may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Injection site reactions: pain, erythema, or swelling at the subcutaneous injection site. - Nausea: mild to moderate feeling of queasiness. - Fatigue: general tiredness or lack of energy.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or anaphylaxis. - Splenic rupture: rare but potentially life‑threatening abdominal event. - Severe leukopenia: marked decrease in white blood cells.

When using Mozobil, several precautions should be observed to ensure patient safety and product integrity. - Dose adjustment: individualize dosing based on stem cell mobilization response and renal function. - Concomitant G‑CSF: coordinate with granulocyte‑colonystimulating factor as recommended in transplant protocols. - Monitoring: perform complete blood count and assess for leukopenia before and after administration. - Pregnancy: avoid use during pregnancy unless benefits outweigh risks, as safety data are limited. - Hypersensitivity: discontinue if signs of severe allergic reaction occur. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Plerixafor can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - None identified: no major drug‑drug interactions have been reported for plerixafor. - Live vaccines: immunosuppression from stem cell mobilization may increase risk of infection.

Moderate Interactions (Monitor Closely): - Concomitant chemotherapy agents: may increase risk of cytopenias. - Anticoagulants: monitor for bleeding if thrombocytopenia occurs. - Other stem cell mobilizers: avoid overlapping use to prevent excessive mobilization.